U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 423 results

Status:
US Approved Rx (2023)
First approved in 2023

Class (Stereo):
CHEMICAL (ABSOLUTE)



Pirtobrutinib is a small molecule, noncovalent inhibitor of BTK. BTK is a signaling protein of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signaling results in activation of pathways necessary for B-cell prolifer...
Status:
US Approved Rx (2023)
First approved in 2022

Class (Stereo):
CHEMICAL (ABSOLUTE)



Bexagliflozin, sold under the brand name Brenzavvy, is a potent and selective SGLT2 inhibitor. By inhibiting SGLT2, bexagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary...
Status:
US Approved Rx (2022)
First approved in 2022

Class (Stereo):
CHEMICAL (ACHIRAL)



Tapinarof (also known as benvitimod, WB-1001; GSK-2894512), a therapeutic aryl hydrocarbon receptor agonist that selectively modulates the cytokine cascade deep under the skin, a process that rapidly decreases inflammations and skin plague. Tapinaro...
Status:
US Approved Rx (2021)
First approved in 2021

Class (Stereo):
CHEMICAL (ABSOLUTE)



Ponesimod is an experimental drug for the treatment of multiple sclerosis (MS) graft-versus-host disease and psoriasis. It acts on certain types of white blood cells (lymphocytes) which are involved in the autoimmune attack on myelin seen in multiple...
Status:
US Approved Rx (2021)
First approved in 2021

Class (Stereo):
CHEMICAL (ABSOLUTE)



Ibrexafungerp (BREXAFEMME®) is an orally active triterpenoid antifungal drug being developed by SCYNEXIS, Inc. for the treatment of fungal infections. The inhibition of β-1,3-D glucan synthetase by ibrexafungerp compromises the integrity of fungal ce...
Status:
US Approved Rx (2021)
First approved in 2021

Class (Stereo):
CHEMICAL (ABSOLUTE)



Cabotegravir is an investigational drug that is being studied for the treatment and prevention of HIV infection. Cabotegravir belongs to a class (group) of HIV drugs called integrase inhibitors. Integrase inhibitors block an HIV enzyme called integra...
Status:
US Approved Rx (2021)
First approved in 2021

Class (Stereo):
CHEMICAL (RACEMIC)



Viloxazine is a selective norepinephrine reuptake inhibitor that has a long history of clinical use in Europe as an antidepressant. An immediate-release formulation was approved for the treatment of depression in the UK in 1974, and was subsequently ...
Status:
US Approved Rx (2019)
First approved in 2019

Class (Stereo):
CHEMICAL (ACHIRAL)



Tafamidis meglumine (Vyndaqel®, Pfizer) is a novel, first-in-class drug for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP), a rare neurodegenerative disorder characterized by progressive sensory, motor and autonomic impairme...
Status:
US Approved Rx (2019)
First approved in 2019

Class (Stereo):
CHEMICAL (EPIMERIC)



ODM-201 (also known as BAY-1841788) is a non-steroidal antiandrogen, specifically, a full and high-affinity antagonist of the androgen receptor (AR), that is under development by Orion and Bayer HealthCare for the treatment of advanced, castration-re...
Status:
US Approved Rx (2019)
First approved in 2019

Class (Stereo):
CHEMICAL (ACHIRAL)



Triclabendazole, (brand name Avomec, Egaten, etc) is a member of the benzimidazole family of anthelmintics used to treat liver flukes, specifically fascioliasis and paragonimiasis. Triclabendazole used routinely since 1983 in veterinary practice for ...